Radiopharm Theranostics Ltd (ASX:RAD)'s Riccardo Canevari and professor Susann Brady-Kalnay join Proactive to discuss the company's new sublicence for a brain tumour-targeting technology. PTPµ (also known as PTPmu), the target of the treatment, is a unique biomarker present in tumourous cells. Under its sublicensing agreement, Radiopharm has the right to develop a PTPµ-targeted agent as an imaging diagnostic. The agent will also be developed as a targeted radiopharmaceutical theranostic for RAD's clinical development pipeline.
Radiopharm Theranostics sublicenses brain tumour-targeting technology
